Efficacy of infliximab in treatment-naïve patients with stricturing small bowel Crohn’s disease

References

• Zhulina Y, Udumyan R, Tysk C, et al. The changing face of Crohn’ disease: a population-based study of the natural history of Crohn’s disease in Örebro, Sweden 1963–2005. Scand J Gastroenterol. 2016;51(3):304–313.
   PubMed Web of Science ®Google Scholar
• Sunada K, Shinozaki S, Nagayama M, et al. Long-term outcomes in patients with small intestinal strictures secondary to Crohn’s disease after double-balloon endoscopy-assisted balloon dilation. Inflamm Bowel Dis. 2016;22(2):380–386.
   PubMed Web of Science ®Google Scholar
• Rieder F, Zimmermann EM, Remzi FH, et al. Crohn’s disease complicated by strictures: a systematic review. Gut. 2013;62(7):1072–1084.
   PubMed Web of Science ®Google Scholar
• Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006.
   PubMed Web of Science ®Google Scholar
• Bettenworth D, Bokemeyer A, Kou L, et al. Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn’s disease strictures. Aliment Pharmacol Ther. 2020;52(7):1104–1116.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Pugliese N, Peyrin-Biroulet L, et al. Efficacy of anti-TNFαdrugs in patients with stricturing Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2020;14(5):347–353.
   PubMed Web of Science ®Google Scholar
• Frei R, Fournier N, Zeitz J, et al. Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn’s disease: 10-year-follow-up data from the Swiss IBD cohort study. J Crohns Colitis. 2019;13(10):1292–1301.
   PubMed Web of Science ®Google Scholar
• Jongsma M, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. Gut. 2020. DOI:10.1136/gutjnl-2020-322339
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25.
   PubMed Web of Science ®Google Scholar
• Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. Scand J Gastroenterol. 2008;43(8):948–954.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Lago I, Hoyo JD, Pérez-Girbés A, et al. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease. United Eur Gastroenterol J. 2020;8(9):1056–1066.
   PubMed Web of Science ®Google Scholar
• Vogel J, Da LMA, Baker M, et al. CT enterography for Crohn’s disease: accurate preoperative diagnostic imaging. Dis Colon Rectum. 2007;50(11):1761–1769.
   PubMed Web of Science ®Google Scholar
• Bruining DH, Zimmermann EM, Loftus EJ, et al. Consensus recommendations for evaluation, interpretation, and utilization of computed tomography and magnetic resonance enterography in patients with small bowel Crohn’s disease. Radiology. 2018;286(3):776–799.
   PubMed Web of Science ®Google Scholar
• Nahon S, Lahmek P, Paupard T, et al. Diagnostic delay is associated with a greater risk of early surgery in a French cohort of Crohn’s disease patients. Dig Dis Sci. 2016;61(11):3278–3284.
   PubMed Web of Science ®Google Scholar
• Schoepfer A, Santos J, Fournier N, et al. Systematic analysis of the impact of diagnostic delay on bowel damage in paediatric versus adult onset Crohn’s disease. J Crohns Colitis. 2019;13(10):1334–1342.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8(4):357–363.
   PubMed Web of Science ®Google Scholar
• Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–512.
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135.
   PubMed Web of Science ®Google Scholar
• Green CJ, Mee AS. Re-introduction of azathioprine in previously intolerant patients. Eur J Gastroenterol Hepatol. 2006;18(1):17–19.
   PubMed Web of Science ®Google Scholar
• Rieder F, Bettenworth D, Ma C, et al. An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. Aliment Pharmacol Ther. 2018;48(3):347–357.
   PubMed Web of Science ®Google Scholar
• Nahon S, Lahmek P, Lesgourgues B, et al. Diagnostic delay in a French cohort of Crohn’s disease patients. J Crohns Colitis. 2014;8(9):964–969.
   PubMed Web of Science ®Google Scholar
• Bouhnik Y, Carbonnel F, Laharie D, et al. Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018;67(1):53–60.
   PubMed Web of Science ®Google Scholar
• Allocca M, Bonifacio C, Fiorino G, et al. Efficacy of tumour necrosis factor antagonists in stricturing Crohn’s disease: a tertiary center real-life experience. Dig Liver Dis. 2017;49(8):872–877.
   PubMedGoogle Scholar
• Fernandes SR, Bernardo S, Simões C, et al. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(2):263–270.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Benchimol EI, Bernstein CN, et al. Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications. J Crohns Colitis. 2020;14(10):1354–1363.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517.
   PubMed Web of Science ®Google Scholar
• Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP consensus on surgery for Crohn’s disease. J Crohns Colitis. 2018;12(1):1–16.
   PubMed Web of Science ®Google Scholar
• Ponsioen CY, de Groof EJ, Eshuis EJ, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017;2(11):785–792.
   PubMed Web of Science ®Google Scholar
• Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s disease: surgical treatment. J Crohns Colitis. 2020;14(2):155–168.
   PubMed Web of Science ®Google Scholar
• Stevens TW, Haasnoot ML, D'Haens GR, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol Hepatol. 2020;5(10):900–907.
   PubMed Web of Science ®Google Scholar
• Shukla R, Thakur E, Bradford A, et al. Caregiver burden in adults with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2018;16(1):7–15.
   PubMed Web of Science ®Google Scholar